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Letters to the EditorImmunodeficiency and disseminatedmycobac-
terial infection associated with homozygous
nonsense mutation of IKKb
To the Editor:
Nuclear factor kappa B (NF-kB) signaling is known to be
important for host protection against infection. For activation,
proteins of the NF-kB transcription factor must be released from
constitutive interaction with inhibitory IkB proteins (IkBa, IkBb,
and IkBε), which sequester NF-kB complexes in the cytoplasm.
This occurs through phosphorylation and degradation of IkB
proteins by the upstream IkB kinase (IKK) complex, for example,
following stimulation of cell surface receptors. The IKK complex
consists of 2 catalytically active kinases, IKKa and IKKb, and the
regulatory subunit IKKg, also known as NF-kB essential
modulator (NEMO). In the canonical pathway of NF-kB
activation, IkBa undergoes IKKb-dependent phosphorylation
and ubiquitin-mediated degradation, liberating the NF-kB
heterodimer, which then translocates to the nucleus.1 Mutations
in 2 proteins of the NF-kB signaling pathway, NEMO and
IkBa, have been described in humans and result in immunodefi-
ciency (ID), usually associated with ectodermal dysplasia (EDA).
Hypormorphic hemizygote NEMO mutations cause X-linked
EDA-ID, while hypermorphic IkBa mutations lead to an
autosomal-dominant EDA-ID.2-4 Affected individuals are
susceptible to severe infections with pyogenic bacteria and
mycobacteria and in some cases opportunistic and viral
pathogens.5 In addition, an autosomal-recessive mutation in
IKKa has been associated with an in utero lethal Cocoon
syndrome characterized by multiple fetal malformations.6
Here, we report an 18-month-old female, second child of
first-degree consanguineous parents from the Arabian Peninsula
(see Fig E1, A, in this article’s Online Repository at www.
jacionline.org), who presented at age 2 months with omphalitis
and delayed separation of the umbilical cord, necessitating surgi-
cal removal. At age 3 months, she developed Salmonella sepsis
and subsequently suffered severe recurrent infections caused by
a range of organisms including Acinetobacter, Enterobacter,
Stenotrophomonas, and Achromobacter species, rotavirus, and
Candida. Chronic diarrhea and a generalized maculopapular
rash were persistent from the neonatal period. Disseminated
BCGosis was diagnosed from skin and gut biopsies, and
antimycobacterial treatment started at age 4 months. Her family
history was significant for a brother who had died at age 1 month
from E coli sepsis and meningitis. In addition, 3 paternal grand
uncles had died in infancy with short febrile illnesses.
At the age of 18 months, our patient had conical teeth,
hepatosplenomegaly, and a severe skin rash (Fig 1, A and B).
This was confirmed to be persistent BCGosis on skin biopsy
showing a mixed inflammatory infiltrate and possible epithelioid
granuloma formation (Fig E1, B), with acid-fast bacilli visible
and a PCR positive for DNA ofMycobacterium tuberculosis com-
plex, but negative for the esat-6 gene. Initial immunologyinvestigations demonstrated normal proportions and numbers of
naive and memory T, B, and natural killer cells, normal T-cell
repertoire, and T-cell proliferation to PHA (Table I). Expression
of MHC class II molecules was preserved. Neutrophil number,
respiratory burst, and integrin expression were normal, as was
phenotyping for monocytes and dendritic cell populations.
Immunoglobulin levels had been documented to be low on repeated
sampling at age 3 months (IgG 1.2 g/L, IgA < 0.05 g/L, and
IgM < 0.05 g/L) and therefore immunoglobulin replacement had
already been commenced. Liver function test results were normal
(including aspartate transaminase, gamma-glutamyl transpepti-
dase, alkaline phosphatase, albumin, total protein, and total bili-
rubin levels). Whole blood cytokine assays on 2 occasions
demonstrated severely impaired production of IFN-g to all stimuli,
absent production of IL-17, and a markedly reduced production of
the proinflammatory cytokines, TNF-a and IL-6, in response to a
range of Toll-like receptor ligands (Fig 1,C). Stimulated IL-12 pro-
duction was also reduced and not significantly rescued by addition
of exogenous IFN-g. The pattern of cytokine response and clinical
features were not consistent with a classical IL-12/INF-g pathway
defect but would be consistent with a defect in the NF-kB pathway.
Our patient7was treatedwith ethambutol, rifampicin, isoniazid,
and pyridoxine as well as prophylactic azithromycin, fluconazole,
and intravenous immunoglobulin in view of her immunodefi-
ciency. INF-g treatment was added at 50 mg/m2 and gradually
increased to 200 mg/m2.7 This was not well tolerated, and she
developed ulcerating skin inflammation and increasing
hepatosplenomegaly necessitating low-dose steroid treatment
(0.5 mg/kg) and therefore IFN-g treatment was withdrawn. She
continued to have recurrent episodes of fever and increased
inflammatory markers that most likely reflected her BCGosis.
She subsequently developed a progressive respiratory distress,
was admitted to intensive care for noninvasive ventilation, and,
unexpectedly, died from amassive gastrointestinal and pulmonary
hemorrhage after a surgical central line insertion at age 25months.
To identify the causative mutation, we used exome sequencing.
Blood sample of the patient was obtained with informed consent
from the parents in accordance with the Declaration of Helsinki
and with approval from the ethics committees (04/Q0501/119 and
06/Q0508/16). Library preparation, exome capture, and
sequencing have been done according to the manufactures
instructions. For exome target enrichment, Agilent SureSelect
50 Mb kit was used. Sequencing was done using Illumina HiSeq
with 94 bp paired-end reads. In the exome data, we found 22,754
single-nucleotide variants and small insertions/deletions,
including 172 very rare ones, that is, those not seen in the 1000
Genomes database (April 2012 data release) and our internal
databases. Five of these variants were homozygous (see Table E1
in this article’s Online Repository at www.jacionline.org).
Among these we identified a homozygous nonsense mutation
c.321C>A in the IKBKB gene that encodes the IKKb protein,
leading to a premature stop codon p.Y107X (Fig 1, D; see Fig
E2, A, in this article’s Online Repository at www.jacionline.
org). In the exome sequence data, we found no mutations in genes
encoding IkBa, NEMO, or other proteins of the NF-kB pathway.
Because gene IKBKG that encodes NEMOwas poorly covered in
the exome data, we studied it by Sanger sequencing and again
found no mutations. We then confirmed the IKBKB mutation by215
FIG 1. A and B, Photographs showing conical teeth, hepatosplenomegally, and widespread rash. C, Quan-
titation of cytokine release from patient and healthy control PBMCs following in vitro activation with various
stimuli (y-axis). Representative data from 1 of 2 repeat experiments are shown. D, Sequence data for the
index case showing the homozygous c.321C>A mutation. E, Western blot showing that the IKKb protein
is present in the healthy donor (HD) but is absent from the patient’s (P) PBMCs.
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gous carriers of this mutation (Fig E2, B). We then purified pro-
teins from PBMCs and demonstrated that the patient
completely lacked IKKb expression (Fig 1, E). We used poly-
clonal rabbit anti-IKKb antibody (Cell Signaling Technology
cat no. 2678) produced by immunizing animals with a synthetic
peptide corresponding to residues surrounding Leu570 of the
756 amino acid IKKb protein. Therefore, presence of a shorter
IKKb protein that potentially could be generated after reinitiation
of translation seems unlikely. Further functional experimentswere not possible, because no patient-derived cell lines were
available after the patient’s death. Given that functional reconsti-
tution experiments were impossible, we cannot formally prove
that the IKKb deficiency has caused the immune phenotype of
the patient, although it is very likely in the absence of other candi-
date loss-of-function mutations. However, additional unknown
modifier genetic or nongenetic factors may have affected the
severity of the patient’s phenotype.
Herewe demonstrate that an autosomal-recessive human IKKb
deficiency has a clinical presentation, which resembles both
TABLE I. Immunology investigations
Cell type Patient’s (age 20 mo) results Age-matched control range
White cell count 8.42 3 109/L (5.0-15.0) 3 109/L
Neutrophil count 3.87 3 109/L (1.0-8.5) 3 109/L
Lymphocyte count 4.03 3 109/L (3.0-13.5) 3 109/L
CD3 T cells 89.0%, 3.37 3 109/L 39%-73%, (1.8-8.0) 3 109/L
CD19 B cells 7.0%, 0.27 3 109/L 17%-41%, (0.6-3.1) 3 109/L
CD161CD561 natural killer cells 3.0%, 0.11 3 109/L 3%-16%, (0.1-1.4) 3 109/L
CD31CD41 T cells 61.0%, 2.31 3 109/L 25%-50%, (0.9-5.5) 3 109/L
CD31CD81 T cells 27.0%, 1.02 3 109/L 11%-32%, (0.4-2.3) 3 109/L
Naive T cells (CD41CD45RA1CD271) 90.0% 62%-90%
Naive T cells (CD81CD45RA1CD271) 98.0% 46%-85%
Naive B cells (CD191IgD1CD272) 98.0%* 42.6%-82.3%
Nonswitched memory B cells (CD191IgD1CD271) 1.0%* 7.4%-32.5%
Class switched memory B cells (CD191IgD2CD271) 0.2%* 6.5%-29.1%
Transitional B cells (CD191IgM11CD3811) 6.0%* 0.6%-3.4%
Plasmablasts (CD191CD3811IgMwk) 0.0%* 0.4%-3.6%
CD21 low B cells (CD191CD21wkCD38wk) 2.0% 0.9%-7.6%
IgM/IgD B cells Present Present
IgG 6.37 g/L after IVIG 3.1-13.8 g/L
IgA <0.23 g/L* 0.3-1.2 g/L
IgM 3.57 g/L* 0.5-2.2 g/L
IVIG, Intravenous immunoglobulin therapy.
*Abnormal result.
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prominent susceptibility to mycobacteria and an increased
frequency of other bacterial infections. No loss-of-function
alleles in the IKBKB gene were previously found in up to 6500
healthy subjects (National Heart, Lung, and Blood Institute
exome variant server, accessed May 2013), suggesting that such
mutations are likely to be pathogenic. Recently, a conference
abstract has been published describing a group of patients with
severe combined immunodeficiency with agammaglobulinemia
that were associated with a frameshift mutation in the IKBKB
gene, which apparently led to an abolished IKKb expression.8
In contrast to our patient, they had reduced numbers of natural
killer cells and manifested with invasive bacterial and viral, but
not mycobacterial, infections. Furthermore, no ectodermal
dysplasia was reported, which distinguishes them from our
patient and most patients with NEMO and IkBa mutations.5
The reasons for such discrepancies should be clarified when a
more detailed description of those patients is published.
The IKKb-deficient mouse embryos die because of liver
degeneration and apoptosis.9-11 In contrast, our data suggest
that humans with the IKKb deficiency can be viable. This is
potentially explained by the compensatorymechanisms involving
IKKa and the noncanonical pathway of NF-kB activation that are
unlikely to be affected by the IKKb deficiency. Interestingly,
while NF-kB activation in cells of the IKKb-deficient mice was
significantly impaired, it was not completely abolished, as resid-
ual signaling was mediated by IKKa.9,10 In the absence of IKKb,
IKKa can make homodimers, which can bind NEMO and
phosphorylate IkBa, thus partially compensating for the loss of
the IKKa/IKKb heterodimers.9,12 We did not observe significant
biochemical liver disease in our patient, which may also relate to
compensatory mechanisms or result from species variation.
The severe granulomatous reaction seen in our patient may be a
feature of systemic infection.13 However, altered keratinocyte
function may additionally cause skin inflammation because
mice with epidermis-specific deletion of IKKb develop a severeTNF-mediated inflammatory skin disease.14 Our patient had
chronic diarrhea, similar to most of the patients with the IkBa
mutations. This is consistent with the importance of the NF-kB
pathway for mucosal immunity, maintaining intestinal epithelia
integrity and homeostasis in the gut.15 In line with other defects
of NF-kB signaling, hypogammaglobulinemia and ectodermal
dysplasia, characterized by peg teeth, were features of IKKb
deficiency in our case. The immunological phenotypewas charac-
terized by a profound defect in the production of proinflammatory
cytokines despite intact development of all immune cell lineages.
Although the clinical spectrum of the condition will be clarified
by the identification of other affected families, the severity of
immunodeficiency in our patient and failure to respond to conser-
vative therapy suggest that bone marrow transplantation should
be considered for children with complete IKKb deficiency.
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http://dx.doi.org/10.1016/j.jaci.2013.12.1093A case of partial dedicator of cytokinesis 8
deficiency with altered effector phenotype
and impaired CD81 and natural killer cell
cytotoxicity
To the Editor:
Hyper-IgE syndrome (HIES) is a primary immunodeficiency
characterized by recurrent infections predominantly involving the
skin and lungs, chronic eczema, high serum IgE levels, and
eosinophilia. HIES has diverse modes of inheritance. Autosomal-
dominant HIES (Mendelian Inheritance in Man [MIM] no.
147060) is caused by mutations in the signal transducer and
activator of transcription 3 gene. Most cases of autosomal-
recessive HIES are caused by mutations in the gene encoding
the dedicator of cytokinesis 8 (DOCK8) (MIM no. 243700).
DOCK8 deficiency is characterized clinically by recurrent viral,
fungal, and sinopulmonary infections.1-4 These patients also have
severe atopic dermatitis, allergies, and an increased likelihood of
developing cancer. DOCK8 deficiency affects both innate and
adaptive immunity and causes combined immunodeficiency.
We present a patient who fulfilled clinical and immunological
parameters for HIES (see the Case report section in this article’s
Online Repository at www.jacionline.org). Mutations in the
signal transducer and activator of transcription 3 gene were ruled
out. At this stage, a DOCK8 deficiency was suspected. Using
comparative genome hybridization, a heterozygous deletion of
exons 2 to 8 was identified in the DOCK8 gene (see Fig E1, A,
in this article’s Online Repository at www.jacionline.org).
Sequence analysis also demonstrated a heterozygous G >
A mutation at position 15 in the 59 splice donor site of intron
17 (IVS1715 G>A) deleting the exon 17 (Genbank
KC736820). This alteration corresponded to a deletion in the
conserved DHR1 domain of the protein (Fig E1, B and C) and
was absent in 50 healthy donors. Some normal DOCK8 tran-
scripts were present, indicating that the exon 17 splicing mutation
did not abrogate normal processing of this allele (Fig E1, D).
DOCK8 transcript expressionwas lower in the patient than in con-
trols in PBMCs, aswell as CD41 and natural killer (NK) cells (Fig
E1, E); however, the DOCK8 protein was clearly detected in the
patient by Western blot, albeit at reduced levels. On the basis of
these findings, we conclude that this is a new case of partial
DOCK8 deficiency (Fig E1, F).
Abnormalities in the T-cell compartment have been described
in classical DOCK8 deficiency,2-4 and we decided to assess the
impact of a partial DOCK8 deficiency on T-cell phenotype and
function. Our patient showed defective thymopoiesis with an
absence of T-cell receptor rearrangement excision circles,
reduced recent thymic emigrants, a restricted T-cell repertoire,
and decreased naive CD41 T cells in PBMCs (Table I; see Fig
E2, A, B, and C, and Fig E3, A, in this article’s Online Repository
at www.jacionline.org). Furthermore, there was an increase in
plasma levels of IL-7 (Table I), which could reflect a compensa-
tory attempt to boost the expansion of recent thymic emigrants
cells to overcome the depletion of peripheral CD41 T cells. Inter-
estingly, in spite of naive CD41 T-cell lymphopenia, the patient’s
T-cell proliferation was unaffected and similar to that in controls
(Fig E3, B). This could be related to the nonexhausted phenotype
showed by the patient, with normal levels of T-effector memory
CD45RA (TEMRA) CD81 T cells (Fig E3, A), in contrast to
classical loss-of-function/expression of DOCK8 in patients
FIG E1. A,Genealogical tree for the kindred. Arrow highlights index case. Asterisks denote family members
who died within the first 2 months of life with febrile illnesses. B, Histology showing granuloma in skin by
hematoxylin and eosin staining.
J ALLERGY CLIN IMMUNOL
VOLUME 134, NUMBER 1
LETTERS TO THE EDITOR 218.e1
FIG E2. A, Schematic IKBKB gene showing the mutation identified in our family. B, Sequence data for the
index case, parents, and healthy control showing heterozygous carriage of the c.321C>A mutation in both
parents.
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TABLE E1. Rare coding homozygous variants found by exome sequencing
Chr Position Ref/Obs Transcript cDNA (change) Gene Amino acid
1 109,276,144 —/T ENST00000370017 c.2130_2131insT
(frameshift insertion)
FNDC7 (fibronectin type III domain containing 7) p.K710fs
1 116,280,898 C/T ENST00000261448 c.G479A (nsSNV) CASQ2 (calsequestrin 2) p.R160H
1 120,168,566 G/A ENST00000421812 c.C158T (nsSNV) ZNF697 (zinc finger protein 697) p.P53L
2 216,197,149 A/G ENST00000236959 c.A733G (nsSNV) ATIC (5-aminoimidazole-4-carboxamide ribonucleotide
formyltransferase/IMP cyclohydrolase)
p.N245D
8 42,150,963 C/A ENST00000520810 c.C321A (stopgain SNV) IKBKB (inhibitor of kappa light polypeptide gene enhancer
in B cells, kinase beta)
p.Y107X
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